Results 91 to 100 of about 7,633 (200)

Not Your Typical Ulcerative Colitis Patient [PDF]

open access: yesModern Medicine
Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU   +3 more
doaj   +1 more source

A rare case of mesalamine-induced eosinophilic pleural effusion

open access: yesThe Journal of Association of Chest Physicians
We present a very rare case of a 47-year-old man with a history of ulcerative colitis (UC), referred to as a case of an undiagnosed bilateral pleural effusion.
Ankit Bhatia   +4 more
doaj   +1 more source

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine [PDF]

open access: yes, 2013
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop.
Moss, Alan, Nanda, Kavinderjit
core   +1 more source

Mesalamine intolerance in three children with Crohn’s disease

open access: yes, 2015
Objective: To present the mesalamine-induced acute exacerbation of symptoms and inflammatory markers in children with Crohn's disease (CD). Clinical Presentation and Intervention: Three children who presented with CD had acute exacerbation of colitis ...
Girgin, Nurten   +9 more
core   +1 more source

Therapeutic potential of mesalamine-probiotic combination in enteric-coated tablet for modulating gut inflammation in IBD

open access: yesJournal of Applied Pharmaceutical Research
Background: Mesalamine is widely used for inflammatory bowel disease (IBD) due to its local anti-inflammatory action, while probiotics help restore intestinal microbiota and modulate immune responses. Combining both may offer synergistic benefits for IBD
Pratiksha A. Thete   +2 more
doaj   +1 more source

Simple one-pot green method for large-scale production of mesalamine, an anti-inflammatory agent

open access: yesGreen Processing and Synthesis, 2019
We report a rapid and efficient synthesis protocol for mesalamine via a green approach with 2-chloro-5-nitrobenzoic acid as the starting material, for its large-scale production.
Vijaya Lakshmi C.   +2 more
doaj   +1 more source

Acute pancreatitis associated with mesalamine: A case report and review of the literature

open access: yes, 1996
Mesalamine, widely used in the treatment of chronic inflammatory bowel disease, has been associated in some patients with the development of acute pancreatitis.
GALLERANI M.   +11 more
core  

Mesalamine-induced myopericarditis in children: a case report and a short revision of the literature [PDF]

open access: yes
Mesalamine has a central role in the treatment of inflammatory bowel disease (IBD). Myocarditis and/or pericarditis are rare and severe side effects of mesalamine-containing drugs.
Montanari F.   +5 more
core   +1 more source

Stability Enhancement of Mesalamine Delayed-Release Tablets 1.2g [PDF]

open access: yes
Mesalamine (5-aminosalicylic acid) is widely used for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis. Commercially available mesalamine delayed-release formulations, such as LIALDA (Mesalamine) Delayed-Release Tablets 1.2
Anonymous,
core  

Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.

open access: yes, 2014
Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.
Ma Somsouk (283498)   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy